Exploring the Association between Icodextrin and Encapsulating Peritoneal Sclerosis

Jenkins S.B. , Leng Bl , Shortland J.R. , Brown P.W. , Wilkie M.E. Sclerosing encapsulating peritonitis: a case series from a single U.K. center during a 10-year period. Adv Perit Dial 2001; 17: 191–5.

wilkie M.E. , Plant M.J. , Edwards L. , Brown C.B. Icodextrin 7.5% dialysate solution (glucose polymer) in patients with ultrafiltration failure: extension of CAPD technique survival. Perit Dial Int 1997; 17: 84–7.

Paniagua R. , Ventura M.D. , Avila-Díaz M. , Cisneros A. , Vicenté–Martínez M. , Furlong M.D. Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients. Perit Dial Int 2009; 29: 422–32.

Sampimon D.E. , Coester A.M. , Struijk D.G. , Krediet R.T. The time course of peritoneal transport parameters in peritoneal dialysis patients who develop encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2011; 26: 291–8.

Augustine T. , Brown P.W. , Davies S.D. , Summers A.M. , Wilkie M.E. Encapsulating peritoneal sclerosis: clinical significance and implications. Nephron Clin Pract 2009; 111: c149–54.

Gotloib L. , Wajsbrot V. , Shostak A. Icodextrin-induced lipid peroxidation disrupts the mesothelial cell cycle engine. Free Radic Biol Med 2003: 34: 419–28.

Martikainen T.A. , Teppo A.M. , Grönhagen-Riska C. , Ekstrand A.V. Glucose-free dialysis solutions: inductors of inflammation or preservers of peritoneal membrane? Perit Dial Int 2005; 25: 453–60.

Moriishi M. , Kawanishi H. , Tsuchiya S. Impact on peritoneal membrane of use of icodextrin-based dialysis solution in peritoneal dialysis patients. Adv Perit Dial 2006; 22: 24–8.

Martis L. , Patel M. , Giertych J. , Mongoven J. , Taminne M. , Perrier M.A. Aseptic peritonitis due to peptidoglycan contamination of pharmacopoeia standard dialysis solution. Lancet 2005; 365: 588–94.

Chan T.M. , Yung S. Studying the effects of new peritoneal dialysis solutions on the peritoneum. Perit Dial Int 2007; 27(Suppl 2): S87–93.

Davies S.J. , Brown E.A. , Frandsen N.E. , Rodrigues A.S. , Rodriguez-Carmona A. , Vychytil A. on behalf of the EAPOS Group. Longitudinal membrane function in functionally anuric patients treated with APD: data from EAPOS on the effects of glucose and icodextrin prescription. Kidney Int 2005; 67: 1609–15.

Nomoto Y. , Kawaguchi Y. , Kubo H. , Hirano H. , Sakai S. , Kurokawa K. Sclerosing encapsulating peritonitis in patients undergoing continuous ambulatory peritoneal dialysis: a report of the Japanese Sclerosing Encapsulating Peritonitis Study Group. Am J Kidney Dis 1996; 28: 420–7.

Rigby R.J. , Hawley C.M. Sclerosing peritonitis: the experience in Australia. Nephrol Dial Transplant 1998; 13: 154–9.

Churchill D.N. , Taylor D.W. , Keshaviah P.R. , and the CANUSA Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. J Am Soc Nephrol 1996; 7: 198–207.

Brown E.A. , Davies S.J. , Rutherford P. , Meeus F. , Borras M. , Riegel W. on behalf of the EAPOS Group. Survival of functionally anuric patients on automated peritoneal dialysis: the European APD Outcome Study. J Am Soc Nephrol 2003; 14: 2948–57.

Habib A.M. , Preston E. , Davenport A. Risk factors for developing encapsulating peritoneal sclerosis in the icodextrin era of peritoneal dialysis prescription. Nephrol Dial Transplant 2010; 25: 1633–8.

Davies S.J. , Woodrow G. , Donovan K. , Plum J. , Williams P. , Johansson A.C. Icodextrin improves the fluid status of peritoneal dialysis patients: results of a double-blind randomized controlled trial. J Am Soc Nephrol 2003; 14: 2338–44.

Han S.H. , Ahn S.V. , Yun J.Y. , Tranæus A. , Han D.S. Mortality and technique failure in peritoneal dialysis patients using advanced peritoneal dialysis solutions. Am J Kidney Dis 2009; 54: 711–20.

Brimble K.S. , Walker M. , Margetts P.J. , Kundhal K.K. , Rabbat C.G. Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol 2006; 17: 2591–8.

kawaguchi Y. , Kawanishi H. , Mujais S. , Topley N. , Oreopoulos D.G. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20(Suppl 4): S43–55.

Brown M.C. , Simpson K. , Kerssens J.J. , Mactier R.A. on behalf of the Scottish Renal Registry. Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. Clin J Am Soc Nephrol 2009; 4: 1222–9.

Davies S.J. , Phillips L. , Naish P.F. , Russell G.I. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12: 1046–51.

Lambie Ml , John B. , Mushahar L. , Huckvale C. , Davies S.J. The peritoneal osmotic conductance is low well before the diagnosis of encapsulating peritoneal sclerosis is made. Kidney Int 2010; 78: 611–18.

Balasubramaniam G. , Brown E.A. , Davenport A. , Cairns H. , Cooper B. , Fan Sl The Pan-Thames EPS study: treatment and outcomes of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2009; 24: 3209–15.